ALK-Abelló A/S Due Diligence

Run due diligence on ALK-Abelló A/S: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by LUNDBECKFONDEN (Denmark) · alk.net · 12 vendors

ALK-Abelló A/S is a Denmark-based global specialty pharmaceutical company focused on allergy, with over a century of experience in allergy immunotherapy research and treatment. The company develops and markets allergy solutions including sublingual immunotherapy tablets, allergy vaccines, diagnostics, and anaphylaxis treatments, reaching over 3 million patients annually across 46 markets worldwide. Headquartered in Hørsholm, Denmark, ALK operates production sites in Denmark, the USA, Spain, and France, and is listed on NASDAQ Copenhagen.

Resilience scores

Technology vendors

Insights

Last updated 2026-11-10 · revision 2

12 direct vendors, 106 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

11 in-scope frameworks identified; showing 3.

GDPR (source) — Evidence found

The company is established in Denmark (an EU member state) and processes the personal data of individuals in the EU, including healthcare professionals, shareholders, and clinical trial participants.

Evidence: https://www.alk.net/terms-and-conditions/privacy-notice/side-effects, https://www.alk.net/terms-and-conditions/privacy-notice/newsletter, https://www.alk.net/ru/terms-and-conditions/privacy-notice, https://ir.alk.net/static-files/519c0c4c-0c95-4d9c-bc9b-d11e33978490, https://alkpro.net/privacy-notice/, https://alkpro.co.uk/privacystatement/

EU GCP — Evidence found

ALK-Abelló A/S conducts clinical trials in the European Union to support the development and approval of its pharmaceutical products, making it subject to Good Clinical Practice (GCP) guidelines.

Evidence: https://ir.alk.net/static-files/519c0c4c-0c95-4d9c-bc9b-d11e33978490, https://www.alk.net/terms-and-conditions/privacy-notice/side-effects, https://www.alk.net/terms-and-conditions/privacy-notice/newsletter, https://en.wikipedia.org/wiki/ALK-Abell%C3%B3, https://lundbeckfonden.com/business-activities/strategic-ownerships/alk-abello-a/s, https://alkpro.net/privacy-notice/

EU IVDR — No public evidence

ALK-Abelló A/S previously had an In Vitro Diagnostics business unit, and while it was closed in 2006, any remaining or future IVD products would be subject to the IVDR.

Financials

Three-year financials

Financial Resilience Score: 9/10

ALK-Abelló demonstrates exceptional financial resilience underpinned by seven consecutive years of revenue and earnings growth, a market-leading position in allergy immunotherapy, and a highly conservative capital structure. The company ended 2025 with net interest-bearing debt of DKK -822 million (i.e., net cash) and a NIBD/EBITDA ratio of -0.4, well below its own maximum target of 2.0. Free cash flow turned strongly positive at DKK 1,432 million in 2025 (from DKK -204 million previously), enabling resumption of dividends at approximately 30% of net profit. Operating performance has accelerated sharply, with EBIT margin expanding from ~14% in 2023 to ~26% in 2025, and Q1 2026 reaching 32% margin. Growth is broad-based across all three regions (Europe, North America, International Markets) and across product lines, with tablets (+17%) and anaphylaxis (+34%) leading in 2025. A current ratio of 3.25 and moderate debt load, combined with new product launches (neffy®, paediatric ACARIZAX, ITULAZAX) and a phase III-ready peanut SLIT program, support a robust forward outlook. Key risks include European pricing/reimbursement pressure (notably German rebate changes), geographic concentration in Europe (~72-74% of revenue), partner dependence in China and Japan, and a rapidly rising cost base (capacity costs +22% in 2025).

Key strengths: Seven consecutive years of revenue and earnings growth, Net cash position: NIBD of DKK -822M; NIBD/EBITDA of -0.4 vs. target max of 2.0, EBIT margin expansion from ~14% (2023) to ~26% (2025), Strong free cash flow of DKK 1,432M in 2025, Current ratio of 3.25 with moderate debt, Market-leading niche in allergy immunotherapy with high regulatory barriers, Diversified pipeline including neffy®, peanut SLIT, and paediatric launches, Double-digit growth across all three regions in 2026, Resumed dividend payments (~30% payout ratio)

Risk factors: European pricing and reimbursement pressure, notably German rebate changes, Geographic concentration in Europe (~72-74% of revenue), China/Japan exposure dependent on licensing and partner phasing, Rising cost base with capacity costs +22% in local currencies in 2025, Partner dependence (ARS Pharma for neffy, GenSci in China, Shionogi/Torii in Japan), UK market access slowdown noted in H1 2026

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report